The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean ...

Facing the fact that Lundbeck’s unexpected offer for Avadel was sweeter, Alkermes has come back to the negotiating table with ...

The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...

Amid the pharma industry's breakneck onshoring push this past year, North Carolina has been a major beneficiary as investment announcements rolled in from the likes of ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...

When Ali Sullivan enrolled at Indiana University, she thought she wanted to become a speech pathologist. Midway through her college career, however, she changed her mind and her career path. | In a ...

After a legal saga involving thousands of civil lawsuits, a Supreme Court ruling and what was once one of America’s ...

Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

Following the FDA’s September announcement of a crackdown on direct-to | Monday, the FDA’s Office of Prescription Drug ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...